[EN] 2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS [FR] UTILISATION DE DERIVES DE 2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL COMME ANTAGONISTES DES RECEPTEURS DU NR2B
[Cp*RhCl2]2, catalyzes efficiently the transferhydrogenation of various quaternary pyridinium salts under mild conditions, affording not only piperidines but also 1,2,3,6‐tetrahydropyridines in a highly chemoselective fashion, depending on the substitution pattern at the pyridinium ring. The reduction is conducted in azeotropic formic acid/triethylamine (HCOOH‐Et3N) mixture at 40 °C, with catalyst loadings
of various nitrogenheterocycles, including but not limited to quinolines, isoquinolines, indoles and pyridinium salts, in an aqueous solution of HCO2H/HCO2Na under mild conditions. The catalyst shows excellent functional‐group compatibility and high turnover number (up to 7500), with catalyst loadings as low as 0.01 mol % being feasible. Mechanistic investigation of the quinolinereduction suggests
在温和条件下,显示出环金属化的铱络合物在HCO 2 H / HCO 2 Na的水溶液中催化各种氮杂环的转移加氢反应,包括但不限于喹啉,异喹啉,吲哚和吡啶鎓盐。该催化剂表现出出色的官能团相容性和高周转率(最高7500),催化剂用量低至0.01 mol%是可行的。对喹啉还原反应的机理研究表明,转移氢化反应是通过1,2和1,4加成途径进行的,催化转化受氢化物转移步骤的限制。
2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
申请人:McCauley A John
公开号:US20060160853A1
公开(公告)日:2006-07-20
2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases.